Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Girish Dhall, MD
University of Alabama at Birmingham
Study Director - Matthias A Karajannis, MD, MS
Memorial Sloan Kettering Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Alabama at Birmingham (site 700)
Birmingham, Alabama, United States
- Univ of California @ Los Angeles (site 325)
Los Angeles, California, United States
- Children's National Medical Center (site 775)
Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta (site 950)
Atlanta, Georgia, United States
- Lurie Childrens Hospital of Chicago (site 350)
Chicago, Illinois, United States
- University of Chicago (site 850)
Chicago, Illinois, United States
- Indiana University (site 400)
Indianapolis, Indiana, United States
- Johns Hopkins University (site 250)
Baltimore, Maryland, United States
- Children's Hospital Boston (site 725)
Boston, Massachusetts, United States
- Washington University - St. Louis (site 900)
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center (site 210)
New York, New York, United States
- New York University Medical Center (site 200)
New York, New York, United States
- Cincinnati Children's Hospital Medical Center (site 800)
Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia (site 750)
Philadelphia, Pennsylvania, United States
- Childrens Medical Center - Univ. of Texas Sw (site 917)
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Feb 2020
- Primary completion
- 25 Feb 2025
- Completion
- 25 Feb 2025
- Last update posted
- 13 Mar 2026
- Registered enrollment
- 12
- Registry id
- NCT04283669
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.